

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/196283 A1

(51) International Patent Classification:

C07D 403/04 (2006.01) C07D 471/04 (2006.01)
C07D 403/14 (2006.01) C07D 487/04 (2006.01)
C07D 401/14 (2006.01) C07D 498/18 (2006.01)
C07D 405/14 (2006.01) A61P 35/00 (2006.01)
C07D 413/14 (2006.01) A61K 45/06 (2006.01)
C07D 417/14 (2006.01)

(21) International Application Number:

PCT/US2023/017384

(22) International Filing Date:

04 April 2023 (04.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/327,631 05 April 2022 (05.04.2022) US

(71) Applicant: **BLUEPRINT MEDICINES CORPORATION** [US/US]; 45 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **AHMAD, Omar**; 45 Sidney Street, Cambridge, MA 02139 (US). **BARVIAN, Kevin, K.**; 45 Sidney Street, Cambridge, MA 02139 (US). **CAMPBELL, John, Emmerston**; 45 Sidney Street, Cambridge, MA 02139 (US). **DINEEN, Thomas, A.**; 45 Sidney Street, Cambridge, MA 02139 (US). **ENO, Meredith, Suzanne**; 45 Sidney Street, Cambridge, MA 02139 (US). **FERNANDO, Dilinice, Prasadhini**; 45 Sidney Street, Cambridge, MA 02139 (US). **PEROLA, Emanuele**; 45 Sidney Street, Cambridge, MA 02139 (US). **RIBEIRO DA SILVA, Vinicius, Barros**; c/o Iktos S.A., 65 rue de Prony, 75017 Paris (FR). **PERRON, Quentin**; c/o Iktos S.A., 65 rue de Prony, 75017 Paris (FR).

(74) Agent: **DAVIS, Steven, G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).



Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: EGFR INHIBITORS



(57) Abstract: The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.



WO 2023/196283 A1